Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Active not recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Melanoma 8Carcinoma, Renal Cell 5Carcinoma, Non-Small-Cell Lung 4Prostatic Neoplasms 3Neoplasm Metastasis 3Lung Neoplasms 3Histiocytoma, Malignant Fibrous 3Urinary Bladder Neoplasms 2Urethral Neoplasms 2Ureteral Neoplasms 2Thyroid Neoplasms 2Sarcoma 2Myelodysplastic Syndromes 2Meningioma 2Glioblastoma 2Carcinoma, Transitional Cell 2Carcinoma, Basal Cell 2Vulvar Neoplasms 1Urogenital Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Somatostatinoma 1Small Cell Lung Carcinoma 1Seminoma 1Recurrent Squamous Cell Lung Carcinoma 1Rectal Neoplasms 1Rare Diseases 1Pseudomyxoma Peritonei 1Pheochromocytoma 1

Interventions

Radiosurgery 3pembrolizumab 2Nivolumab 2Ipilimumab 2CTLA-4 Antigen 2ribociclib 1lutetium Lu 177 dotatate 1abemaciclib 1Specimen Handling 1Mental Status and Dementia Tests 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Meningioma × CTLA-4 Antigen × Clear all
NCT03604978 2026-05-13

Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
38 enrolled
CNS

Meningioma

NCT02648997 2026-01-26

An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
40 enrolled 14 charts
CNS

Meningioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡